Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 8/20 | 0.35 |
| ▸ | CDK1 | P06493 | 8/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.33 |
| ▸ | BTK | Q06187 | 3/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | ITK | Q08881 | 2/20 | 0.32 |
| ▸ | PDE8B | O95263 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27156794 | 1.00 | AURKA (0.35) | AURKACDK1AURKBHRH3BTK | |
| SCHEMBL27156349 | 1.00 | AURKA (0.35) | AURKACDK1AURKBHRH3BTK | |
| SCHEMBL27156738 | 0.97 | AURKA (0.35) | AURKACDK1AURKBHRH3PDE8B | |
| SCHEMBL27156730 | 0.97 | AURKA (0.35) | AURKACDK1AURKBHRH3PDE8B | |
| SCHEMBL27156740 | 0.93 | KMO (0.30) | — | |
| SCHEMBL27156591 | 0.93 | KMO (0.30) | — | |
| SCHEMBL27156555 | 0.90 | AURKA (0.35) | AURKACDK1AURKBHRH3BTK | |
| SCHEMBL27156527 | 0.90 | AURKA (0.37) | AURKACDK1AURKBHRH3PDE8B | |
| SCHEMBL27156880 | 0.90 | AURKA (0.37) | AURKACDK1AURKBHRH3PDE8B | |
| SCHEMBL29819812 | 0.87 | AURKA (0.34) | AURKACDK1AURKBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | AURKA 522/4885CDK1 118/4885AURKB 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.